Presentation Type
Oral Presentation
Discipline Track
Biomedical Science
Abstract Type
Research/Clinical
Abstract
Breast cancer is the second leading cause of cancer-related deaths in women, after lung cancer. Unfortunately, it is the primary cause of death among Hispanic women. Approximately 10-20% of breast cancers are classified as basal (triple-negative) subtypes, which are challenging to treat due to the absence of specific targets. Triple-negative breast cancer is a highly aggressive and lethal type of tumor, particularly among Hispanic women, with a poor prognosis compared to other breast cancer subtypes. Therefore, it is crucial to identify new molecules with therapeutic and prognostic values to treat this evolving disease. Multiple studies have demonstrated that X-linked genes are associated with cancer. Although these genes are tightly regulated and expressed only in immune-privileged organs, many become abnormally expressed in tumors.
Our genomic analysis has revealed that newly annotated X-linked genes previously thought to be gene deserts in the human genome are highly antigenic and cancer testis-antigens (CT genes). However, little information exists about their expression and role in triple-negative breast cancer. To fill this gap, we have used an integrated genomic approach to identify testis-tissue-specific genes differentially expressed in this type of breast cancer. Additionally, we have discovered a highly immunogenic cancer-testis gene using cutting-edge technology-driven (Global Run-On Sequencing) gene expression analysis. With cell- , mouse-based, and genomic approaches, we have mechanistically found that this CT gene modulates gene expression, immune response, and tumor growth in triple-negative breast cancer. This finding can potentially revolutionize the diagnosis and treatment of this type of breast cancer.
Academic/Professional Position
Graduate Student
Recommended Citation
Sedano, Melina J.; Harrison, Alana L.; Reid, Victoria; Dhandayuthapani, Subramanian; and Gadad, Shrikanth S., "The role of a cancer testis-antigen in regulating tumor growth and oncogenic pathways in triple-negative breast cancer." (2024). Research Symposium. 42.
https://scholarworks.utrgv.edu/somrs/2024/talks/42
Included in
The role of a cancer testis-antigen in regulating tumor growth and oncogenic pathways in triple-negative breast cancer.
Breast cancer is the second leading cause of cancer-related deaths in women, after lung cancer. Unfortunately, it is the primary cause of death among Hispanic women. Approximately 10-20% of breast cancers are classified as basal (triple-negative) subtypes, which are challenging to treat due to the absence of specific targets. Triple-negative breast cancer is a highly aggressive and lethal type of tumor, particularly among Hispanic women, with a poor prognosis compared to other breast cancer subtypes. Therefore, it is crucial to identify new molecules with therapeutic and prognostic values to treat this evolving disease. Multiple studies have demonstrated that X-linked genes are associated with cancer. Although these genes are tightly regulated and expressed only in immune-privileged organs, many become abnormally expressed in tumors.
Our genomic analysis has revealed that newly annotated X-linked genes previously thought to be gene deserts in the human genome are highly antigenic and cancer testis-antigens (CT genes). However, little information exists about their expression and role in triple-negative breast cancer. To fill this gap, we have used an integrated genomic approach to identify testis-tissue-specific genes differentially expressed in this type of breast cancer. Additionally, we have discovered a highly immunogenic cancer-testis gene using cutting-edge technology-driven (Global Run-On Sequencing) gene expression analysis. With cell- , mouse-based, and genomic approaches, we have mechanistically found that this CT gene modulates gene expression, immune response, and tumor growth in triple-negative breast cancer. This finding can potentially revolutionize the diagnosis and treatment of this type of breast cancer.